These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35520020)

  • 1. [Market surveillance and control of substandard, falsified and unregistered medicines: integrative reviewVigilancia y control de medicamentos subestándar, falsificados y no registrados: una revisión integral].
    Martins MAF; Scherer MDDA; Lucchese G
    Rev Panam Salud Publica; 2022; 46():e36. PubMed ID: 35520020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard, falsified and unregistered medicines in Latin America, 2017-2018.
    Rojas-Cortés R
    Rev Panam Salud Publica; 2020; 44():e125. PubMed ID: 33033498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country.
    Khurelbat D; Dorj G; Sunderland B; Sanjjav T; Bayarsaikhan E; Damdinjav D; Dorj G; Jigjidsuren A; Lkhagvasuren O; Erdenetsetseg B
    BMC Public Health; 2020 May; 20(1):743. PubMed ID: 32434489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems.
    Chabalenge B; Jere E; Nanyangwe N; Hikaambo C; Mudenda S; Banda M; Kalungia A; Matafwali S
    J Med Access; 2022; 6():27550834221141767. PubMed ID: 36601496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study.
    Higgins CR; Kobia B; Ozawa S
    PLoS One; 2023; 18(1):e0268661. PubMed ID: 36652447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority.
    Mori AT; Meena E; Kaale EA
    BMJ Open; 2018 Jun; 8(6):e021825. PubMed ID: 29950474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
    Iloh GU; Akodu BA; Emeka EA; Obi IV
    West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.
    Ozawa S; Higgins CR; Nwokike JI; Phanouvong S
    Am J Trop Med Hyg; 2022 Jul; 107(1):14-20. PubMed ID: 35895357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
    Machado Reis AT; Berardo BFR; Loureiro R
    PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
    Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
    Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
    [No Abstract]   [Full Text] [Related]  

  • 17. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines.
    Akpobolokemi T; Martinez-Nunez RT; Raimi-Abraham BT
    J Med Access; 2022; 6():23992026211070406. PubMed ID: 36204519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives.
    Ahmed J; Modica de Mohac L; Mackey TK; Raimi-Abraham BT
    J Med Access; 2022; 6():23992026221074548. PubMed ID: 36204527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.
    Opuni KF; Nettey H; Larbi MA; Amartey SNA; Nti G; Dzidonu A; Owusu-Danso P; Owusu NA; Nyarko AK
    Malar J; 2019 Dec; 18(1):403. PubMed ID: 31805937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries.
    Rasheed H; Höllein L; Holzgrabe U
    Front Pharmacol; 2018; 9():995. PubMed ID: 30233373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.